Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease
Authors
Keywords
-
Journal
CNS DRUGS
Volume 32, Issue 8, Pages 797-806
Publisher
Springer Nature America, Inc
Online
2018-08-07
DOI
10.1007/s40263-018-0552-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
- (2018) Robert A. Hauser et al. CLINICAL PHARMACOKINETICS
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
- (2018) Lawrence W. Elmer et al. CNS DRUGS
- L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey
- (2017) S. Perez-Lloret et al. EUROPEAN JOURNAL OF NEUROLOGY
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
- (2017) Robert A. Hauser et al. Journal of Parkinsons Disease
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
- (2014) Eva Schaeffer et al. CNS DRUGS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Therapies in Parkinsonʼs disease
- (2012) Joseph Jankovic et al. CURRENT OPINION IN NEUROLOGY
- Amantadine: The journey from fighting flu to treating Parkinson disease
- (2012) G. Hubsher et al. NEUROLOGY
- Therapies for dopaminergic-induced dyskinesias in parkinson disease
- (2011) Mildred D. Gottwald et al. ANNALS OF NEUROLOGY
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Molecular mechanisms underlying levodopa-induced dyskinesia
- (2008) Paolo Calabresi et al. MOVEMENT DISORDERS
- Suicidal and death ideation in Parkinson's disease
- (2008) Sarra Nazem et al. MOVEMENT DISORDERS
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Molecular mechanisms of L-DOPA-induced dyskinesia
- (2008) Peter Jenner NATURE REVIEWS NEUROSCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started